{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T19:54:36Z","timestamp":1776455676046,"version":"3.51.2"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"DOI":"10.1186\/s12917-025-04592-4","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T08:03:53Z","timestamp":1740816233000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preserved bevacizumab (Avastin\u00ae) eye drops for application in multidose containers \u2013 an in-vitro characterisation"],"prefix":"10.1186","volume":"21","author":[{"given":"Ulrike","family":"Lessiak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Brandstoetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Nell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klara","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Mlynek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Wimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Scheiblecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Tichy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Hoelbl-Kovacic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"issue":"4","key":"4592_CR1","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","volume":"127","author":"MH Dastjerdi","year":"2009","unstructured":"Dastjerdi MH, Al-Arfaj KM, Nallasamy N, Hamrah P, Jurkunas UV, Pineda R, Pavan-Langston D, Dana R. Topical bevacizumab in the treatment of corneal neovascularization: results of prespective, open-label, noncomparative study. Arch Ophthalmology. 2009;127(4):381\u20139.","journal-title":"Arch Ophthalmology"},{"key":"4592_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/ICO.0000000000002502","volume":"40","author":"T Hayashi","year":"2021","unstructured":"Hayashi T, Zhang W, Hos D, Schrittenlocher S, Le VNH, Siebelmann S, Matthaei M, Bock F, Bachmann B, Cursiefen C. Descemet membrane endothelial keratoplasty in vascularized eyes: outcome and effect on corneal neovascularization. Cornea. 2021;40:685\u20139.","journal-title":"Cornea"},{"key":"4592_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2020.108363","volume":"202","author":"MP Nicholas","year":"2021","unstructured":"Nicholas MP, Mysore N. Corneal neovascularization. Exp Eye Res. 2021;202: 108363.","journal-title":"Exp Eye Res"},{"key":"4592_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/ICO.0000000000001127","volume":"36","author":"T Inomata","year":"2017","unstructured":"Inomata T, Mashaghi A, Di Zazzo A, Lee SM, Chiang H, Dana R. Kinetics of angiogenic responses in corneal transplantation. Cornea. 2017;36:491\u20136.","journal-title":"Cornea"},{"issue":"3","key":"4592_CR5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.ophtha.2011.01.041","volume":"118","author":"S Maddula","year":"2011","unstructured":"Maddula S, Davis DK, Maddula S, Burrow MK, Ambati BK. Horizons in therapy for corneal angiogenesis. Ophthalmology. 2011;118(3):591\u20139.","journal-title":"Ophthalmology"},{"issue":"3","key":"4592_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0039-6257(98)00035-6","volume":"43","author":"P Lee","year":"1998","unstructured":"Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol. 1998;43(3):245\u201369.","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"4592_CR7","first-page":"21","volume":"23","author":"NA Antonia","year":"2014","unstructured":"Antonia NA, Anoop N, M.K., Anoop, S., Devanand, C.B., Martin, J., Venugopal S.K. Occurrence of ophthalmic disorders in dogs. Indian J Vet Res. 2014;23(2):21\u20134.","journal-title":"Indian J Vet Res"},{"issue":"1","key":"4592_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/vop.12571","volume":"22","author":"AMM Shank","year":"2019","unstructured":"Shank AMM, Teixeria LBC, Dubielzig RR. Canine, feline, and equine corneal vascular neoplasia: a retrospective study (2007\u20132015). Veterinary Ophthalmology. 2019;22(1):76\u201387.","journal-title":"Veterinary Ophthalmology"},{"key":"4592_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1463-5224.2010.00858.x","volume":"14","author":"J Dreyfus","year":"2011","unstructured":"Dreyfus J, Schobert CS, Dubielzig RR. Superficial corneal squamous cell carcinoma occurring in dogs with chronic keratitis. Vet Ophthalmol. 2011;14:161\u20138.","journal-title":"Vet Ophthalmol"},{"key":"4592_CR10","first-page":"1","volume":"00","author":"AP Lisankis","year":"2022","unstructured":"Lisankis AP, Beavis BB, Weigt AK, Nunnery C. A case of malignant transformation of equine immune-mediated keratitis to B-cell lymphoma. Equine Veterinary Education. 2022;00:1\u20136.","journal-title":"Equine Veterinary Education"},{"key":"4592_CR11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/vop.12275","volume":"19","author":"LV Vallone","year":"2016","unstructured":"Vallone LV, Neaderland MH, Ledbetter EC, Dubielzig RR. Suspected malignant transformation of B lymphocytes in the equine cornea from immune-mediated keratitis. Vet Ophthalmol. 2016;19:172\u20139.","journal-title":"Vet Ophthalmol"},{"key":"4592_CR12","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/978-1-4615-5359-5_132","volume":"438","author":"R Kaswan","year":"1998","unstructured":"Kaswan R, Pappas C Jr, Wall K, Hirsh SG. Survey of canine tear deficiency in veterinary practice. Adv Exp Med Biol. 1998;438:931\u20139.","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"4592_CR13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1177\/1098612X12472181","volume":"15","author":"E Dean","year":"2013","unstructured":"Dean E, Meunier V. Feline eosinophilic keratoconjunctivitis: a retrospective study of 45 cases (56 eyes). J Feline Med Surg. 2013;15(8):661\u20136.","journal-title":"J Feline Med Surg"},{"key":"4592_CR14","first-page":"1160","volume-title":"Veterinary Ophthalmology","author":"DVH Hendrix","year":"2013","unstructured":"Hendrix DVH. Diseases and Surgery of the Canine Anterior Uvea. In: Gelatt KN, Gilger BC, Kern TJ, editors. Veterinary Ophthalmology, vol. two. 5th ed. Ames: Wiley Blackwell; 2013. p. 1160\u20133.","edition":"5"},{"issue":"12","key":"4592_CR15","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1016\/j.cclet.2021.03.037","volume":"32","author":"X Li","year":"2021","unstructured":"Li X, Liu H, Yu A, Lin D, Bao Z, Wang Y, Li X. Bioinspired self-assembly supramolecular hydrogel for ocular drug delivery. Chin Chem Lett. 2021;32(12):3936\u20139.","journal-title":"Chin Chem Lett"},{"key":"4592_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.colsurfb.2017.07.057","volume":"159","author":"J Huang","year":"2017","unstructured":"Huang J, Wang W, Yu J, Yu X, Zheng Q, Peng F, He Z, Zhao W, Zhang Z, Li X, Wang Q. Combination of dexamethasone and Avastin\u00ae by supramolecular hydrogel attenuates the inflammatory corneal neovascularization in rat alkali burn model. Colloids Surf, B. 2017;159:241\u201350.","journal-title":"Colloids Surf, B"},{"issue":"625","key":"4592_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.122081","volume":"25","author":"H Shi","year":"2022","unstructured":"Shi H, Zhu Y, Xing C, Li S, Bao Z, Lei L, Lin D, Wang Y, Chen H, Xu X. An injectable thermosensitive hydrogel for dual delivery of diclofenac and Avastin\u00ae to effectively suppress inflammatory corneal neovascularization. Int J Pharm. 2022;25(625): 122081.","journal-title":"Int J Pharm"},{"issue":"1","key":"4592_CR18","first-page":"18","volume":"39","author":"S Amano","year":"1998","unstructured":"Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39(1):18\u201322.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4592_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1463-5224.2011.00973.x","volume":"15","author":"DR Binder","year":"2012","unstructured":"Binder DR, Herring IP, Zimmerman KL, Phillip Pickett J, Huckle WR. Expression of vascular endothelial growth factor receptor-1 and -2 in normal and diseased canine eyes. Veterinary Ophthalmology. 2012;15:223\u201330.","journal-title":"Veterinary Ophthalmology"},{"key":"4592_CR20","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/ICU.0b013e3282f0ca54","volume":"18","author":"C Andreoli","year":"2007","unstructured":"Andreoli C, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007;18:502\u20138.","journal-title":"Curr Opin Ophthalmol"},{"issue":"4","key":"4592_CR21","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.ophtha.2006.12.028","volume":"114","author":"JF Arevalo","year":"2007","unstructured":"Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, Berrocal MH, Solis-Vivanco A, Farah ME. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema. Results from the Pan-American collaborative retina study group at 6-month follow-up. Ophthalmology. 2007;114(4):743\u201350.","journal-title":"Ophthalmology"},{"issue":"3","key":"4592_CR22","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(3):363\u201372.","journal-title":"Ophthalmology"},{"issue":"3","key":"4592_CR23","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1177\/11206721211073405","volume":"32","author":"A Beccasio","year":"2022","unstructured":"Beccasio A, Mignini C, Caricato A, Iaccheri B, Di Cara G, Verrotti A, Cagini C. New trends in intravitreal anti-VEGF therapy for ROP. Eur J Ophthalmol. 2022;32(3):1340\u201351.","journal-title":"Eur J Ophthalmol"},{"issue":"12","key":"4592_CR24","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"Heier, J.S., Brown, D.M., Chong, V., Korobelnik, J.F., Kaiser, P.K., Nguyen, Q.D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G.D., Stahl, N., Vitti, R., Berliner, A.J., Soo, Y., Anderesi, M., Groetzbach, G., Sommerauer, B., Sandbrink, R., Simader, C., Schmidt-Erfurth, U., VIEW 1 and VIEW 2 Study Groups","year":"2012","unstructured":"Heier, J.S., Brown, D.M., Chong, V., Korobelnik, J.F., Kaiser, P.K., Nguyen, Q.D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G.D., Stahl, N., Vitti, R., Berliner, A.J., Soo, Y., Anderesi, M., Groetzbach, G., Sommerauer, B., Sandbrink, R., Simader, C., Schmidt-Erfurth, U., VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348.","journal-title":"Ophthalmology"},{"key":"4592_CR25","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.ajo.2006.06.066","volume":"142","author":"ME Iliev","year":"2006","unstructured":"Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra G-M. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol. 2006;142:1054\u20136.","journal-title":"Am J Ophthalmol"},{"key":"4592_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/178132","volume":"2014","author":"D Krizova","year":"2014","unstructured":"Krizova D, Vokrojova M, Liehneova K, Studeny P. Treatment of corneal neovascularization using anti-VEGF bevacizumab. Journal of Ophthalmology. 2014;2014:1\u20138.","journal-title":"Journal of Ophthalmology"},{"key":"4592_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1186\/s12886-022-02641-2","volume":"22","author":"Y Wang","year":"2022","unstructured":"Wang Y, Du H, Zhao X, Meng L, Chen Y. Observation, laser photocoagulation or anti-VEGF therapy in the management of retinal arterial macroaneurysms. BMC Ophthalmol. 2022;22:417.","journal-title":"BMC Ophthalmol"},{"issue":"24","key":"4592_CR28","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/vop.12931","volume":"2021","author":"L-M Muellerleile","year":"2021","unstructured":"Muellerleile L-M, Bernkopf M, Wambacher M, Nell B. Topical bevacizumab for the treatment of corneal vascularization in dogs: A case series. Vet Ophthalmol. 2021;2021(24):554\u201368.","journal-title":"Vet Ophthalmol"},{"key":"4592_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajo.2018.01.011","volume":"188","author":"K-H Na","year":"2018","unstructured":"Na K-H, Yoo C, Park J-H, Kim YY. Eye Drop Dispenser Type and Medication Possession Ratio in Patients with Glaucoma: Single-Use Containers Versus Multiple-Use Bottles. Am J Ophthalmol. 2018;188:9\u201318.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"4592_CR30","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.ajo.2012.06.007","volume":"154","author":"SF Cheng","year":"2012","unstructured":"Cheng SF, Dastjerdi MH, Ferrari G, Okanobo A, Bower KS, Ryan DS, Amparo F, Stevenson W, Hamrah P, Nallasamy N, Dana R. Short-term topical bevacizumab in the treatment of stable corneal neovascularization. Am J Ophthalmol. 2012;154(6):940\u20138.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"4592_CR31","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/archopht.125.6.834","volume":"125","author":"JJ DeStafeno","year":"2007","unstructured":"DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol. 2007;125(6):834\u20136.","journal-title":"Arch Ophthalmol"},{"issue":"00","key":"4592_CR32","first-page":"1","volume":"2018","author":"L-M Muellerleile","year":"2018","unstructured":"Muellerleile L-M, Tichy A, Nell B. Serum vascular endothelial growth factor changes and safety after topical anti-human VEGF antibody bevacizumab in healthy dogs. Vet Ophthalmol. 2018;2018(00):1\u20137.","journal-title":"Vet Ophthalmol"},{"issue":"8","key":"4592_CR33","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1097\/IJG.0000000000001867","volume":"30","author":"F Aptel","year":"2021","unstructured":"Aptel F, Villemont AS, Cunnac P, Sallit R, Rabilloud M, Poli M, Denis P. Comparison of Topical Instillation from Single-dose and Multidose Eye Drop Containers in Glaucoma: A Multicenter Randomized Cross-sectional Trial. J Glaucoma. 2021;30(8):718\u201324.","journal-title":"J Glaucoma"},{"issue":"4","key":"4592_CR34","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","volume":"29","author":"C Baudouin","year":"2010","unstructured":"Baudouin C, Labb\u00e9 A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312\u201334.","journal-title":"Prog Retin Eye Res"},{"key":"4592_CR35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ijbiomac.2021.01.075","volume":"172","author":"C Sakuma","year":"2021","unstructured":"Sakuma C, Tomioka Y, Li C, Shibata T, Nakagawa M, Kurosawa Y, Arakawa T, Akuta T. Analysis of protein denaturation, aggregation and post-translational modification by agarose native gel electrophoresis. Int J Biol Macromol. 2021;172:589\u201396.","journal-title":"Int J Biol Macromol"},{"key":"4592_CR36","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/eye.2015.28","volume":"29","author":"H Khalili","year":"2015","unstructured":"Khalili H, Sharma G, Froome A, Khaw PT, Brocchini S. Storage stability of bevacizumab in polycarbonate and polypropylene syringes. Eye. 2015;29:820.","journal-title":"Eye"},{"issue":"9","key":"4592_CR37","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/eye.2013.139","volume":"27","author":"JM Palmer","year":"2013","unstructured":"Palmer JM, Amoaku WM, Kamali F. Quality of bevacizumab compounded for intravitreal administration. Eye (Lond). 2013;27(9):1090\u20137.","journal-title":"Eye (Lond)"},{"issue":"3","key":"4592_CR38","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.idairyj.2004.07.012","volume":"15","author":"S Roufik","year":"2005","unstructured":"Roufik S, Paquin P, Britten M. Use of high-performance size exclusion chromatography to characterize protein aggregation in commercial whey protein concentrates. Int Dairy J. 2005;15(3):231\u201341.","journal-title":"Int Dairy J"},{"issue":"2","key":"4592_CR39","doi-asserted-by":"publisher","first-page":"108","DOI":"10.5935\/0004-2749.20170026","volume":"80","author":"M Sugimoto","year":"2017","unstructured":"Sugimoto M, Toledo V, Cunha M, Carregal VM, Jorge R, Le\u00e3o P, Fialho SL, Silva-Cunha A. Quality of bevacizumab (Avastin\u00ae) repacked in single-use glass vials for intravitreal administration. Arq Bras Oftalmol. 2017;80(2):108\u201313.","journal-title":"Arq Bras Oftalmol"},{"key":"4592_CR40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jchromb.2016.05.045","volume":"1032","author":"I Su\u00e1rez","year":"2016","unstructured":"Su\u00e1rez I, Salmer\u00f3n-Garc\u00eda A, Cabeza J, Capit\u00e1n-Vallvey LF, Navas N. Development and use of specific ELISA methods for quantifying the biological activity of bevacizumab, cetuximab and trastuzumab in stability studies. J Chromatogr B. 2016;1032:155\u201364.","journal-title":"J Chromatogr B"},{"issue":"10","key":"4592_CR41","first-page":"16","volume":"18","author":"S Koza","year":"2022","unstructured":"Koza S, Warren B. Modern Size-Exclusion Chromatography Separations of Biosimilar Antibodies at Physiological pH and Ionic Strength. Column. 2022;18(10):16\u201321.","journal-title":"Column"},{"issue":"3","key":"4592_CR42","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3892\/etm.2022.11493","volume":"24","author":"H Sadick","year":"2022","unstructured":"Sadick H, Sch\u00e4fer E, Weiss C, Rotter N, M\u00fcller CE, Birk R, Sadick M, H\u00e4ussler D. An in-vitro study on the effect of bevacizumab on endothelial cell proliferation and VEGF concentration level in patients with hereditary hemorrhagic telangiectasia. Exp Ther Med. 2022;24(3):555.","journal-title":"Exp Ther Med"},{"issue":"9","key":"4592_CR43","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1016\/j.patcog.2012.03.001","volume":"45","author":"M Gla\u00df","year":"2012","unstructured":"Gla\u00df M, M\u00f6ller B, Zirkel A, W\u00e4chter K, H\u00fcttelmaier S, Posch S. Cell migration analysis: Segmenting scratch assay images with level sets and support vector machines. Pattern Recogn. 2012;45(9):3154\u201365.","journal-title":"Pattern Recogn"},{"issue":"5","key":"4592_CR44","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1007\/s11538-017-0267-4","volume":"79","author":"W Jin","year":"2017","unstructured":"Jin W, Shah ET, Penington CJ, McCue SW, Maini PK, Simpson MJ. Logistic Proliferation of Cells in Scratch Assays is Delayed. Bull Math Biol. 2017;79(5):1028\u201350.","journal-title":"Bull Math Biol"},{"issue":"6","key":"4592_CR45","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/14712598.2022.2078160","volume":"22","author":"VP Chavda","year":"2022","unstructured":"Chavda VP, Prajapati R, Lathigara D, Nagar B, Kukadiya J, Redwan EM, Uversky VN, Kher MN, Patel R. Therapeutic monoclonal antibodies for COVID-19 management: an update. Expert Opin Biol Ther. 2022;22(6):763\u201380.","journal-title":"Expert Opin Biol Ther"},{"issue":"14","key":"4592_CR46","doi-asserted-by":"publisher","first-page":"7542","DOI":"10.3390\/ijms23147542","volume":"23","author":"M Gallazzi","year":"2022","unstructured":"Gallazzi M, Ucciero MAM, Faraci DG, Mahmoud AM, Al Essa W, Gaidano G, Mouhssine S, Cris\u00e0 E. New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Int J Mol Sci. 2022;23(14):7542.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4592_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, Katsarava Z, Maassen Van Den Brink A, Martelletti P, Mitsikostas DD, Ornello R, Reuter U, Sanchez-Del-Rio M, Sinclair AJ, Terwindt G, Uluduz D, Versijpt J, Lampl C. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain. 2022;23(1):67.","journal-title":"J Headache Pain"},{"issue":"2","key":"4592_CR48","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/1574884712666170809124728","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S, Kumar NK, Dwiwedi P, Charan J, Kaur R, Sidhu P, Chugh VK. Monoclonal Antibodies: A Review. Curr Clin Pharmacol. 2018;13(2):85\u201399.","journal-title":"Curr Clin Pharmacol"},{"key":"4592_CR49","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/vop.12580","volume":"22","author":"RA Strauss","year":"2019","unstructured":"Strauss RA, Genschel U, Allbaugh RA, Sebbag L, Ben-Shlomo G. Evaluation of microbial contamination of canine plasma eyedropper bottles following clinical use in canine patients. Vet Ophthalmol. 2019;22:222\u20138.","journal-title":"Vet Ophthalmol"},{"issue":"1","key":"4592_CR50","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1586\/17469899.4.1.59","volume":"4","author":"PD Freeman","year":"2009","unstructured":"Freeman PD, Kahook MY. Preservatives in topical ophthalmic medications: historical and clinical perspectives. Expert Review of Ophthalmology. 2009;4(1):59\u201364.","journal-title":"Expert Review of Ophthalmology"},{"key":"4592_CR51","first-page":"1","volume":"36","author":"MH Goldstein","year":"2021","unstructured":"Goldstein MH, Silva FQ, Blender N, Tran T, Vantipalli S. Ocular benzalkonium chloride exposure: problems an solutions. Eye. 2021;36:1\u20138.","journal-title":"Eye"},{"key":"4592_CR52","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S0002-9394(44)90120-0","volume":"27","author":"KC Swan","year":"1944","unstructured":"Swan KC. Reactivity of the ocular tissues to wetting agents. Am J Ophthalmol. 1944;27:118.","journal-title":"Am J Ophthalmol"},{"issue":"Suppl1","key":"4592_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.survophthal.2003.12.019","volume":"49","author":"JS Cohen","year":"2004","unstructured":"Cohen JS, Gross RL, Cheetham JK, VanDenburgh AM, Bernstein P, Whitcup SM. Two year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol. 2004;49(Suppl1):45\u201352.","journal-title":"Surv Ophthalmol"},{"key":"4592_CR54","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0161-6420(02)01010-2","volume":"109","author":"RL Fellman","year":"2002","unstructured":"Fellman RL, Sullivan EK, Ratliff M, Silver LH, Whitson JT, Turner FD, Weiner AL, Davis AA. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicentertrial. Ophthalmology. 2002;109:998\u20131008.","journal-title":"Ophthalmology"},{"key":"4592_CR55","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1002\/jctb.6765","volume":"97","author":"V Chopda","year":"2022","unstructured":"Chopda V, Gyorgypal A, Yang O, Singh R, Ramachandran R, Zhang H, Tsilomelekis G, Chundawat SPS, Ierapetritou MG. Recent advances in integrated process analytical techniques, modeling, and control strategies to enable continuous biomanufacturing of monoclonal antibodies. J Chem Technol Biotechnol. 2022;97:2317\u201335.","journal-title":"J Chem Technol Biotechnol"},{"issue":"7","key":"4592_CR56","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/bit.23155","volume":"108","author":"M Vazquez-Rey","year":"2011","unstructured":"Vazquez-Rey M, Lang DA. Aggregates in monoclonal antibody manufacturing processes. Biotechnol Bioeng. 2011;108(7):1494\u2013508.","journal-title":"Biotechnol Bioeng"},{"issue":"11","key":"4592_CR57","first-page":"44","volume":"21","author":"RV Cordoba-Rodriguez","year":"2008","unstructured":"Cordoba-Rodriguez RV. Aggregates in MAbs and Recombinant Therapeutic Proteins: A Regulatory Perspective. Biopharm Int. 2008;21(11):44\u201353.","journal-title":"Biopharm Int"},{"issue":"4","key":"4592_CR58","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.xphs.2021.09.030","volume":"111","author":"TK Das","year":"2022","unstructured":"Das TK, Sreedhara A, Colandene JD, Chou DK, Filipe V, Grapentin C, Searles J, Christian TR, Narhi LO, Jiskoot W. Stress Factors in Protein Drug Product Manufacturing and Their Impact on Product Quality. J Pharm Sci. 2022;111(4):868\u201386.","journal-title":"J Pharm Sci"},{"key":"4592_CR59","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3233\/HAB-2011-0244","volume":"20","author":"S Kaja","year":"2011","unstructured":"Kaja S, Hilgenberg JD, Everett E, Olitsky SE, Gossage J, Koulen P. Effects of dilution and prolonged storage with preservatives in a polyethylene container on bevacizumab (Avastin) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies. Hum Antibodies. 2011;20:95\u2013101.","journal-title":"Hum Antibodies"},{"issue":"4","key":"4592_CR60","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1080\/19420862.2018.1452580","volume":"10","author":"N Seo","year":"2018","unstructured":"Seo N, Polozova A, Zhang M, Yates Z, Cao S, Li H, Kuhns S, Maher G, McBride HJ, Liu J. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. mAbs. 2018;10(4):678\u201391.","journal-title":"mAbs"},{"issue":"6","key":"4592_CR61","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/IAE.0b013e3181d50cea","volume":"30","author":"MY Kahook","year":"2010","unstructured":"Kahook MY, Liu L, Ruzycki P, Mandava N, Carpenter JF, Petrash JM, Ammar DA. High-molecular-weight aggregates in repackaged bevacizumab. Retina. 2010;30(6):887\u201392.","journal-title":"Retina"},{"issue":"4","key":"4592_CR62","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11095-018-2368-7","volume":"35","author":"SA Giannos","year":"2018","unstructured":"Giannos SA, Kraft ER, Zhao ZY, Merkley KH, Cai J. Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions. Pharm Res. 2018;35(4):78.","journal-title":"Pharm Res"},{"key":"4592_CR63","doi-asserted-by":"publisher","first-page":"313","DOI":"10.4155\/bio-2016-0269","volume":"9","author":"A Khodabandehloo","year":"2017","unstructured":"Khodabandehloo A, Chen DD. Particle sizing methods for the detection of protein aggregates in biopharmaceuticals. Bioanalysis. 2017;9:313\u201326.","journal-title":"Bioanalysis"},{"issue":"7","key":"4592_CR64","first-page":"369","volume":"73","author":"S Akbas","year":"2018","unstructured":"Akbas S, Sahin A, Calis S, Oncel H, Capan Y. Characterization of bevacizumab by dynamic light scattering while maintaining its native structure. Pharmazie. 2018;73(7):369\u201374.","journal-title":"Pharmazie"},{"key":"4592_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2019.110636","volume":"187","author":"I Roggia","year":"2020","unstructured":"Roggia I, Dalcin AJF, Ourique AF, Da Cruz IBM, Ribeiro EE, Mitjans M, Vinardell MP, Gomes P. Protective effect of guarana-loaded liposomes on hemolytic activity. Colloids Surf, B. 2020;187: 110636.","journal-title":"Colloids Surf, B"},{"issue":"3","key":"4592_CR66","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.pharma.2012.03.006","volume":"70","author":"M Paul","year":"2012","unstructured":"Paul M, Vieillard V, Roumi E, Cauvin A, Despiau MC, Laurent M, Astier A. Long-term stability of bevacizumab repackaged in 1 mL polypropylene syringes for intravitreal administration. Ann Pharm Fr. 2012;70(3):139\u201354.","journal-title":"Ann Pharm Fr"},{"key":"4592_CR67","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jconrel.2014.06.043","volume":"190","author":"YC Kim","year":"2014","unstructured":"Kim YC, Chiang B, Wu X, Prausnitz MR. Ocular delivery of macromolecules. J Control Release. 2014;190:172\u201381.","journal-title":"J Control Release"},{"key":"4592_CR68","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ejpb.2015.07.025","volume":"96","author":"A Quigley","year":"2015","unstructured":"Quigley A, Williams DR. The second virial coefficient as a predictor of protein aggregation propensity: A self-interaction chromatography study. Eur J Pharm Biopharm. 2015;96:282\u201390.","journal-title":"Eur J Pharm Biopharm"},{"key":"4592_CR69","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.cvsm.2004.01.003","volume":"34","author":"GJ Malmberg","year":"2004","unstructured":"Malmberg GJ, Lupo R. Compounding in veterinary ophthalmology. Veterinary Clinics of North America. Small Animal Practice. 2004;34:825\u201338.","journal-title":"Small Animal Practice"},{"key":"4592_CR70","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0039-6257(82)90081-9","volume":"26","author":"J Shell","year":"1982","unstructured":"Shell J. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol. 1982;26:207\u201318.","journal-title":"Surv Ophthalmol"},{"issue":"9","key":"4592_CR71","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1089\/jop.2019.0038","volume":"35","author":"L Sebbag","year":"2019","unstructured":"Sebbag L, Allbaugh RA, Wehrman RF, Uhl LK, Ben-Shlomo G, Chen T, Mochel JP. Fluorophotometric assessment of tear volume and turnover rate in healthy dogs and cats. J Ocul Pharmacol Ther. 2019;35(9):497.","journal-title":"J Ocul Pharmacol Ther."},{"key":"4592_CR72","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v16.i1.20","volume":"16","author":"H Sasaki","year":"1999","unstructured":"Sasaki H, Yamamura K, Mukai T, Nishida K, Nakamura J, Nakashima M, Ichikawa M. Enhancement of ocular drug penetration. Crit Rev Ther Drug Carrier Syst. 1999;16:85\u2013146.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"4592_CR73","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0165-6147(84)90416-4","volume":"5","author":"PN Patil","year":"1984","unstructured":"Patil PN. Some factors which affect the ocular drugresponse. Trends Pharmacol Sci. 1984;5:201\u20134.","journal-title":"Trends Pharmacol Sci"},{"key":"4592_CR74","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.3390\/biom11111610","volume":"11","author":"H Jia","year":"2021","unstructured":"Jia H, Harikumar P, Atkinson E, Rigsby P, Wadhwa M. The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab. Biomolecules. 2021;11:1610.","journal-title":"Biomolecules"},{"key":"4592_CR75","unstructured":"European Medicines Agency (EMA). 2014. Questions and Answers on Benzalkonium chloride in the context of the revision of the guideline on Excipients in the label and package leaflet of medicinal products for human. Doc. Ref. (CPMP\/463\/00) EMA\/495737\/2013. EMEA Headquarters, London. Available at: https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/questions-answers-benzalkonium-chloride-context-revision-guideline-excipients-label-package-leaflet_en.pdf."},{"issue":"4","key":"4592_CR76","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1208\/s12248-018-0230-9","volume":"20","author":"K Vandekerckhove","year":"2018","unstructured":"Vandekerckhove K, Seidl A, Gutka H, Kumar M, Gratzl G, Keire D, Coffey T, Kuehne H. Rational Selection, Criticality Assessment, and Tiering of Quality Attributes and Test Methods for Analytical Similarity Evaluation of Biosimilars. AAPS J. 2018;20(4):68.","journal-title":"AAPS J"},{"key":"4592_CR77","first-page":"29","volume":"22","author":"C Chan","year":"2019","unstructured":"Chan C. Critical Quality Attributes Assessment and Testing Strategy for Biotherapeutics Development. American Pharmaceutical Review. 2019;22:29\u201333.","journal-title":"American Pharmaceutical Review"},{"issue":"5","key":"4592_CR78","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s10637-014-0129-y","volume":"32","author":"Y Liu","year":"2014","unstructured":"Liu Y, Tian H, Blobe GC, Theuer CP, Hurwitz HI, Nixon AB. Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. Invest New Drugs. 2014;32(5):851\u20139.","journal-title":"Invest New Drugs"},{"issue":"3","key":"4592_CR79","first-page":"619","volume":"40","author":"M De Saint Jean","year":"1999","unstructured":"De Saint Jean M, Brignole F, Bringuier AF, Bauchet A, Feldmann G, Baudouin C. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci. 1999;40(3):619\u201330.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-025-04592-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-025-04592-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-025-04592-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T08:37:56Z","timestamp":1740818276000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-025-04592-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4592"],"URL":"https:\/\/doi.org\/10.1186\/s12917-025-04592-4","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"assertion":[{"value":"23 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}